# Nivolumab/Ipilimumab in Second Line CUP-syndrome

> **NCT04131621** · PHASE2 · UNKNOWN · sponsor: **University Hospital Heidelberg** · enrollment: 194 (estimated)

## Conditions studied

- Cancer of Unknown Primary Site

## Interventions

- **BIOLOGICAL:** Nivolumab/Ipilimumab

## Key facts

- **NCT ID:** NCT04131621
- **Lead sponsor:** University Hospital Heidelberg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-12
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 194 (ESTIMATED)
- **Last updated:** 2020-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04131621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04131621, "Nivolumab/Ipilimumab in Second Line CUP-syndrome". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04131621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*